These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14734474)

  • 1. Age-dependent prognostic effects of genetic alterations in glioblastoma.
    Batchelor TT; Betensky RA; Esposito JM; Pham LD; Dorfman MV; Piscatelli N; Jhung S; Rhee D; Louis DN
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):228-33. PubMed ID: 14734474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic analyses for predictors of radiation response in glioblastoma.
    Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic alterations in glioblastomas with oligodendroglial component.
    Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
    Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of loss of heterozygosity with shorter survival in primary glioblastoma patients.
    Jesionek-Kupnicka D; Szybka M; Potemski P; Kulczycka-Wojdala D; Jaskólski D; Bieńkowski M; Skowroński W; Papierz W; Kordek R; Zawlik I
    Pol J Pathol; 2013 Dec; 64(4):268-75. PubMed ID: 24375041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
    Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
    Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastomas with an oligodendroglial component: a pathological and molecular study.
    He J; Mokhtari K; Sanson M; Marie Y; Kujas M; Huguet S; Leuraud P; Capelle L; Delattre JY; Poirier J; Hoang-Xuan K
    J Neuropathol Exp Neurol; 2001 Sep; 60(9):863-71. PubMed ID: 11556543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations in primary glioblastomas in Japan.
    Fukushima T; Favereaux A; Huang H; Shimizu T; Yonekawa Y; Nakazato Y; Ohagki H
    J Neuropathol Exp Neurol; 2006 Jan; 65(1):12-8. PubMed ID: 16410744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil.
    Koshiyama DB; Trevisan P; Graziadio C; Rosa RFM; Cunegatto B; Scholl J; Provenzi VO; de Sá AP; Soares FP; Velho MC; de A P Filho N; Oliveira CA; Zen PRG
    J Neurooncol; 2017 Dec; 135(3):465-472. PubMed ID: 28856550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.
    Bieńkowski M; Piaskowski S; Stoczyńska-Fidelus E; Szybka M; Banaszczyk M; Witusik-Perkowska M; Jesień-Lewandowicz E; Jaskólski DJ; Radomiak-Załuska A; Jesionek-Kupnicka D; Sikorska B; Papierz W; Rieske P; Liberski PP
    PLoS One; 2013; 8(6):e65444. PubMed ID: 23762372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.
    Kaulich K; Blaschke B; Nümann A; von Deimling A; Wiestler OD; Weber RG; Reifenberger G
    J Neuropathol Exp Neurol; 2002 Dec; 61(12):1092-9. PubMed ID: 12484572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
    Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A
    J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The infrequent simultaneous genetic alterations in glioblastoma multiforme (LOH 10, 17, 19q, TP53 mutation and EGFR amplification) with short clinical course.
    Jesionek-Kupnicka D; Kulczycka D; Rieske P; Szybka M; Jabłońska J; Potemski P; Kolasa P; Liberski PP; Kordek R
    Pol J Pathol; 2007; 58(2):79-85. PubMed ID: 17715673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
    Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
    Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characteristics of glioblastoma with 1p/19q co-deletion.
    Mizoguchi M; Yoshimoto K; Ma X; Guan Y; Hata N; Amano T; Nakamizo A; Suzuki SO; Iwaki T; Sasaki T
    Brain Tumor Pathol; 2012 Jul; 29(3):148-53. PubMed ID: 22736234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
    Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
    Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
    J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
    Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
    Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.